220 related articles for article (PubMed ID: 28552212)
1. Clinical trials and drug approvals continue to accelerate in China.
Wang M
Lancet Oncol; 2017 Jul; 18(7):855. PubMed ID: 28552212
[No Abstract] [Full Text] [Related]
2. New Clinical Trial Designs Hasten Approvals for Targeted Therapies.
Schmidt C
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26944760
[No Abstract] [Full Text] [Related]
3. I-SPY 2 may change how clinical trials are conducted: researchers aim to accelerate approvals of cancer drugs.
Printz C
Cancer; 2013 Jun; 119(11):1925-7. PubMed ID: 23695808
[No Abstract] [Full Text] [Related]
4. Accelerated approval and oncology drug development timelines.
Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R
J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846
[No Abstract] [Full Text] [Related]
5. Fast-track approval of medicines in Australia.
Nash L
Lancet Oncol; 2016 Nov; 17(11):1487. PubMed ID: 27693239
[No Abstract] [Full Text] [Related]
6. Clinical trials data collection: when less is more.
Sargent DJ; George SL
J Clin Oncol; 2010 Dec; 28(34):5019-21. PubMed ID: 20921455
[No Abstract] [Full Text] [Related]
7. FDA says it's open to new approaches to cancer trials.
Traynor K
Am J Health Syst Pharm; 2008 May; 65(9):795, 800. PubMed ID: 18436724
[No Abstract] [Full Text] [Related]
8. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
9. Research outcomes and recommendations for the assessment of progression in cancer clinical trials.
Bushnell W; Stone A
J Biopharm Stat; 2013; 23(5):949-50. PubMed ID: 23957508
[No Abstract] [Full Text] [Related]
10. Advancing American Kidney Health (AAKH): Catalyst for Investment in Kidney Diseases Clinical Trials and Precision Medicine: An Opportunity to Advance Upstream Interventions and the Importance of Nephrology.
Fowler KJ
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1689-1691. PubMed ID: 32759179
[No Abstract] [Full Text] [Related]
11. Phase 0 clinical trials: an answer to drug development stagnation?
LoRusso PM
J Clin Oncol; 2009 Jun; 27(16):2586-8. PubMed ID: 19364952
[No Abstract] [Full Text] [Related]
12. Assessing tumor-related signs and symptoms to support cancer drug approval.
Williams G; Pazdur R; Temple R
J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
[TBL] [Abstract][Full Text] [Related]
13. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.
Knopf K; Baum M; Shimp WS; Bennett CL; Faith D; Fishman ML; Hrushesky WJ
BMJ; 2016 Dec; 355():i6286. PubMed ID: 28039123
[No Abstract] [Full Text] [Related]
14. Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.
Vaduganathan M; Butler J; Gheorghiade M
Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27707750
[No Abstract] [Full Text] [Related]
15. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
Tuma RS
J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
[No Abstract] [Full Text] [Related]
16. Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.
Sanyal AJ; Miller V
Gastroenterology; 2016 Jun; 150(8):1723-7. PubMed ID: 26924092
[No Abstract] [Full Text] [Related]
17. Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
Frueh FW; Rudman A; Simon K; Gutman S; Reed C; Dorner AJ
Pharmacogenomics J; 2006; 6(5):296-300. PubMed ID: 16568150
[No Abstract] [Full Text] [Related]
18. 'Basket studies' will hold intricate data for cancer drug approvals.
Willyard C
Nat Med; 2013 Jun; 19(6):655. PubMed ID: 23744135
[No Abstract] [Full Text] [Related]
19. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant trials could speed up drug approvals.
Peres J
J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
[No Abstract] [Full Text] [Related]
[Next] [New Search]
